Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage? - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34277304/

2021 Jul 10;13(7):e16307. doi: 10.7759/cureus.16307. 1 Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, USA. 2 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C., USA. Free PMC article...

CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34277836/

The advent of chimeric antigen receptor T-cell (CAR T-cell) therapy has revolutionized the treatment paradigm of various hematologic malignancies. Ever since its first approval for treatment of acute lymphoblastic leukemia...

Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34302277/

Many patients with DLBCL have long travel times to an academic hospital that administers CAR T cell therapy. Expanding access to care through site-of-care planning will help address regional, rural-urban,...

The use of tafasitamab in diffuse large B-cell lymphoma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34285786/

Patients who relapse or are refractory after first-line therapy for diffuse large B-cell lymphoma (DLBCL) frequently have poor prognoses, especially when they are not candidates for autologous stem cell transplant...

The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34282799/

MYC/BCL2 protein co-expression (i.e., double expressor) has been shown to be a negative predictor of outcome in diffuse large B-cell lymphoma (DLBCL). We aimed to establish the incidence of double...